The price-to-earnings ratio for Sanofi ADR (NASDAQ: SNY) is 20.12x, which is above its average ratio. Moreover, the 36-month beta value for SNY is 0.47. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for SNY is 2.44B and currently, short sellers hold a 0.18% of that float. On July 09, 2025, SNY’s average trading volume was 2.63M shares.
SNY) stock’s latest price update
Sanofi ADR (NASDAQ: SNY)’s stock price has dropped by -0.29% in relation to previous closing price of $48.32. Nevertheless, the company has seen a loss of -0.27% in its stock price over the last five trading days. prnewswire.com reported 2025-07-07 that NEW YORK, July 7, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SNY’s Market Performance
SNY’s stock has fallen by -0.27% in the past week, with a monthly drop of -3.18% and a quarterly drop of -7.31%. The volatility ratio for the week is 1.36% while the volatility levels for the last 30 days are 1.34% for Sanofi ADR. The simple moving average for the past 20 days is -1.17% for SNY’s stock, with a -7.61% simple moving average for the past 200 days.
Analysts’ Opinion of SNY
Many brokerage firms have already submitted their reports for SNY stocks, with Exane BNP Paribas repeating the rating for SNY by listing it as a “Outperform.” The predicted price for SNY in the upcoming period, according to Exane BNP Paribas is $65 based on the research report published on April 15, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see SNY reach a price target of $65. The rating they have provided for SNY stocks is “Neutral” according to the report published on March 21st, 2025.
SNY Trading at -4.78% from the 50-Day Moving Average
After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.85% of loss for the given period.
Stock Fundamentals for SNY
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.71 for the gross margin
The net margin for Sanofi ADR stands at 0.14. The total capital return value is set at 0.08. Equity return is now at value 7.34, with 4.29 for asset returns.
Based on Sanofi ADR (SNY), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is 13.25.
Currently, EBITDA for the company is 11.03 billion with net debt to EBITDA at 1.29. When we switch over and look at the enterprise to sales, we see a ratio of 2.62. The receivables turnover for the company is 97.93for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
To wrap up, the performance of Sanofi ADR (SNY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
